DRUG WARNING: INVIRASE (SAQUINAVIR MESYLATE)

By /

On April 20, 2010, Hoffman LaRoche, in collaboration with Health Canada issued a report describing dose-dependent abnormal electrical activity or conduction in the heart (specifically prolongations of QT and PR intervals) in healthy volunteers.

They suggested that caution be taken in patients with known QT prolongation abnormalities or those taking other medications known to prolong the QT interval and the administration of Invirase.

Physicians should order baseline electrocardiograms (ECGs) for patients for whom they wish to prescribe Invirase. In addition, patients on Invirase experiencing heart palpitations should contact their physician.

For more information: Click here to view the Health Canada advisory

Scroll to Top

Canada Post has provided notification of restarting their operations on December 17, 2024. As Canada Post ramps up and stabilizes their services, the BC-CfE will continue the following measures on an interim basis to minimize service disruption to BC-CfE clients and providers.

  • The BC-CfE Laboratory will utilize private courier for delivery of outgoing reports and documents. (Lab Contact Information: Phone 604-806-8775; FAX 604-806-9463)
  • The BC-CfE Drug Treatment Program (DTP) will fax outgoing forms and documents to the provider’s office. (DTP Contact Information: Phone 604-806-8515; FAX 604-806-9044)
  • St. Paul’s Hospital Ambulatory Pharmacy will utilize private courier for delivery of medications. (Contact Information: Phone 1-800-547-3622; FAX 604-806-8675)

Start typing and press enter to search